ProBioGen Presents GlymaxX - The Novel Glyco-Engineering Technology
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
ProBioGen announces the launch of its Glyco-Engineering Technology "GlymaxX" for the generation of afucosylated antibodies with strongly increased potency.
GlymaxX is a universally applicable technology to enhance the ADCC effector function and thus strongly boosting the cell-killing capability of therapeutic antibodies.
The GlymaxX technology is based on the presence of a heterologous enzyme that interrupts the fucose biosynthesis pathway by capturing a reactive sugar intermediate. As a unique feature, differentiating it from other approaches, the GlymaxX technology can be applied to already existing pharmaceutical antibody producer cell lines without altering their productivity.
The applicability and efficiency of the GlymaxX technology have been confirmed already in feasibility studies of several major European pharmaceutical corporations. The GlymaxX technology is available to interested parties under a license.
GlymaxX is a universally applicable technology to enhance the ADCC effector function and thus strongly boosting the cell-killing capability of therapeutic antibodies.
The GlymaxX technology is based on the presence of a heterologous enzyme that interrupts the fucose biosynthesis pathway by capturing a reactive sugar intermediate. As a unique feature, differentiating it from other approaches, the GlymaxX technology can be applied to already existing pharmaceutical antibody producer cell lines without altering their productivity.
The applicability and efficiency of the GlymaxX technology have been confirmed already in feasibility studies of several major European pharmaceutical corporations. The GlymaxX technology is available to interested parties under a license.
